First Strategy, Now MEI Pharma: Litecoin Joins Bitcoin As Treasury Asset
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 18 2025
0mins
Should l Buy ?
Source: Benzinga
MEI Pharma's Treasury Program: MEI Pharma has launched a $100 million treasury program backed by Titan Partners Group and GSR, appointing Litecoin creator Charlie Lee to its Board of Directors, marking a significant shift towards cryptocurrency investment.
Market Reaction and Significance: Following the announcement, MEI's stock experienced volatility, rising sharply before settling at $6.00, making it the first U.S.-listed company to allocate a substantial treasury position solely in Litecoin, highlighting a growing trend among public companies investing in cryptocurrencies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
